BACKGROUND: @entity1229 therapy in @entity1 with @entity955 markedly reduces the incidence of @entity64 . However, in elderly @entity1 @entity1229 therapy is often underused owing to the perceived higher risk of @entity548 . OBJECTIVES: To assess the quality of anticoagulant control and the incidence of @entity548 and @entity64 in an elderly population (>75 years old) compared with a younger control group (between 60 and 69 years) and to assess the quality of anticoagulant control and incidence of @entity548 in those @entity1 who recently commenced receiving @entity1229 therapy (first year of therapy). @entity1 AND METHODS: In this retrospective follow-up study, anticoagulant control and the incidence of @entity548 and @entity64 were assessed in an elderly population (>75 years old) compared with a younger control group (between 60 and 69 years), all with @entity955 (target international normalized ratio [INR] 2.5) and attending a hospital outpatient anticoagulant clinic. RESULTS: A total of 328 @entity1 were studied over a 21-month period. There were 204 @entity1 in the control group providing 288 @entity1 -years of follow-up and 124 @entity1 in the elderly group providing 170 @entity1 -years of follow-up. The percentage of INR results in the target range was not statistically significantly different between the elderly and control groups (71.5% vs 66.1%) and the occurrences of incidences of INR greater than 7 were 4.2% in the control group and 4.7% in the elderly group (P =.96). The incidences of major @entity548 were 2.8% per year in the elderly group and 2.9% per year in the control group (P =.96); overall incidence was 2.8% (95% confidence interval, 1.3%-4.4%). One hundred one of the 328 @entity1 studied commenced @entity1229 therapy during or within 3 months of the start of the study. In this induction group, 62.1% of INRs were within the target range compared with 70.9% of INRs in @entity1 who had been receiving @entity1229 therapy for more than 3 months at the start of the study (P =.002). The incidences of INR greater than 7 and major @entity548 were 7.9% per year and 6.9% per year, respectively, in the cohort who recently began @entity1229 therapy compared with 3.4% per year and 1.7% per year in the group who were receiving @entity1229 therapy for more than 3 months. CONCLUSION: While it was impossible to consider any selection bias at the level of referral to the clinic, these findings suggest that the elderly population attending our anticoagulant clinic did not have poorer anticoagulant control or an increased incidence of @entity548 while receiving @entity1229 therapy.

Oral anticoagulation and XXXX in an elderly population with @entity955 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity64 :: ('MESH:D020521', 'Disease') :: ['embolic stroke', 'stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic complications', 'hemorrhage'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin', 'Warfarin sodium']
@entity548 :: (MESH:D006470,Disease) :: ['hemorrhagic complications']
